Why Americans Pay Ten Times More for the Same Pill: Lessons from Baltic Pharmacy Models

In Vilnius, the capital of Lithuania, a month's supply of a common blood pressure medication costs the equivalent of roughly five US dollars at a licensed pharmacy. In Chicago or Houston, the same molecule — same active ingredient, same dosage — can retail for upward of sixty dollars even with insurance. Without coverage, the price can climb far higher.

This disparity is not a quirk of currency exchange. It reflects deep structural differences in how Eastern European countries approach pharmaceutical pricing, generic drug access, and the role of the pharmacy within the broader healthcare system. At Aptekai.t, we believe these differences deserve serious attention from American consumers and policymakers alike.

The Price Regulation Difference

Perhaps the most significant factor separating Baltic pharmacy economics from the American model is the presence — or absence — of government price controls on medications.

Lithuania, like most EU member states, operates a national reference pricing system. Under this framework, the government establishes maximum reimbursable prices for covered medications, frequently benchmarking them against prices in neighboring countries. Manufacturers who wish to participate in the public reimbursement system must price their products within these ceilings. The result is a market where pharmaceutical companies compete on cost, rather than simply on brand recognition and direct-to-consumer marketing.

The United States, by contrast, grants pharmaceutical manufacturers considerable latitude in setting their own prices. While insurers and pharmacy benefit managers (PBMs) negotiate discounts and rebates behind the scenes, the list prices of brand-name drugs in America remain among the highest in the developed world. The Inflation Reduction Act of 2022 introduced limited Medicare drug price negotiation for a small number of high-cost medications, but this represents a modest departure from a decades-long tradition of market-driven pharmaceutical pricing.

Generic Drug Accessibility: Where Eastern Europe Excels

In Lithuania and across much of Eastern Europe, generic medications are not merely available — they are actively promoted. Pharmacists are legally empowered, and in many cases professionally encouraged, to offer generic substitutions when a brand-name product is prescribed. Public health campaigns reinforce the message that generics are therapeutically equivalent to their branded counterparts.

This cultural and regulatory environment has produced a market where generics account for the overwhelming majority of dispensed prescriptions by volume. Patients expect affordable alternatives, and the pharmacy system is structured to deliver them.

In the United States, generic penetration is also substantial — generics account for roughly 90 percent of prescriptions filled — but the pricing dynamics remain puzzling. Even generic drugs in America can cost significantly more than their equivalents in Europe, partly because the US lacks a unified pricing mechanism and partly because the supply chain involves multiple intermediary layers, each extracting a margin.

The Pharmacy's Role: Advisor Versus Transaction Point

Another underappreciated distinction lies in the cultural role of the pharmacist. In Lithuania and neighboring Baltic states, the pharmacy is traditionally a first-line healthcare resource. Patients routinely consult pharmacists before visiting a physician, seeking guidance on minor ailments, appropriate OTC remedies, and dosage questions. Pharmacists in this context are active clinical advisors, not merely dispensers of pre-counted pills.

This model has practical cost implications. When a Lithuanian patient develops a minor respiratory infection, a pharmacist consultation — which is free of charge — may result in an appropriate OTC recommendation that resolves the issue without a physician visit, a prescription, or an insurance claim. The downstream savings, aggregated across millions of such interactions annually, are substantial.

American pharmacy culture has evolved somewhat in this direction, particularly as pharmacists have taken on expanded roles in vaccination administration and medication therapy management. However, the structural incentives in the US system — where physician visits and prescription drugs generate revenue in ways that pharmacist consultations historically have not — continue to favor more expensive interventions.

Pharmacy Benefit Structures: Transparency vs. Opacity

One of the most frequently cited frustrations among American healthcare consumers is the opacity of drug pricing. The actual cost of a medication at the pharmacy counter can differ dramatically from its list price, its insurer-negotiated price, and the price a cash-paying patient might secure through a discount program. This complexity is not accidental — it is the product of a system in which multiple parties benefit from informational asymmetry.

Baltic pharmacy systems, while not without their own inefficiencies, tend toward greater price transparency. In Lithuania, the reimbursement framework specifies clearly which medications are covered, at what percentage, and for which patient categories. Patients generally know before they arrive at the pharmacy what they will pay. This predictability reduces both financial anxiety and the likelihood of patients abandoning prescriptions due to unexpected costs.

Prescription abandonment — the practice of leaving a medication at the pharmacy counter because the cost is prohibitive — is a recognized public health problem in the United States, contributing to preventable hospitalizations and worsening chronic disease outcomes. Transparent, regulated pricing structures of the type employed in Lithuania and Poland represent one evidence-based mechanism for reducing this phenomenon.

What the US Could Realistically Adopt

It would be naive to suggest that the United States could simply import the Lithuanian pharmacy model wholesale. The American healthcare system is vastly larger, more complex, and more deeply entrenched in market-based principles than its Baltic counterparts. Political resistance to pharmaceutical price controls remains formidable.

Nevertheless, specific elements of the Eastern European approach are worth serious consideration:

Reference pricing for public payers: Allowing Medicare and Medicaid to benchmark drug costs against prices in comparable countries — a practice already employed in many EU nations — could generate meaningful savings without dismantling the broader market structure.

Expanded pharmacist authority: Empowering pharmacists to counsel patients on cost-effective alternatives, including generics and OTC options, could reduce unnecessary physician visits and prescription costs.

Mandatory price transparency: Requiring clear, advance disclosure of out-of-pocket costs at the pharmacy level would reduce abandonment rates and improve medication adherence.

At Aptekai.t, we do not advocate for any particular political position on US healthcare reform. What we do advocate for is informed dialogue — and the Baltic experience offers genuinely instructive examples of how a well-regulated pharmacy system can serve patients without bankrupting them.